Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Alemtuzumab patient and RA patient control demographic and serological data. CAM prefix denotes alemtuzumab treated patients and CON prefix denotes control patients. aTotal cumulative alemtuzumab dose administerd to RA patients between 1991–1994. bDAS-28-ESR at the baseline visit for this study; cVAS pain patient reported; dSJC: swollen joint count, range 0–28; eTJC: tender joint count, range 0–28; fIgG: normal range: 6-16 g/L; gIgA: normal range: 0.9-4.5 g/L; hIgM normal range: 0.5-2 g/L; iRF titre by direct quantification, IU/ml; positive threshold 14 IU/ml; jCCP: anti-cyclic citrullinated peptide, U/ml, positive threshold 7 U/ml; kDMARD/Biological therapy: MTX - methotrexate; HCQ – hydroxychloroquine; LEF–leflunomide; SSZ-sulphasalazine; ABA–abatacept; ADA – adalimumab; ETA – etanercept; TOC – tocilizumab; n/a: not applicable

From: Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies

  Age
(Years)
Sex Disease Duration
(Years)
Alemtuzumab total dose
(mg)a
DAS-28b CRP
(mg/L)
ESR
(mm/hr)
HAQ VASc SJCd TJCe IgGf
(g/L)
IgAg
(g/L)
IgMh
(g/L)
RFi
(IU)
CCPj
(U/ml)
DMARD
Therapyk
CAM05 55 F 36 250 4.27 4 26 1.625 56 2 6 12.2 2.9 0.06 0 0 AZA, ETA
CAM10 65 M 38 18 3.36 26 34 2.000 25 0 1 10.7 2.3 0.60 0 1.4 LEF, MTX
CAM21 45 F 23 18 1.38 2 4 2.250 18 2 6 n/a n/a n/a 0 0.5 LEF, MTX
CAM26 69 F 26 30 4.74 7 14 2.250 49 0 0 6.2 1.1 0.70 25 0 HCQ, LEF
CAM27 56 M 28 400 2.20 7 15 2.000 8 0 0 8.0 3.2 3.20 0 0.6 MTX
CAM29 81 F 24 30 3.44 7 52 2.250 4 0 0 8.3 1.9 1.00 67 n/a MTX
CAM32 74 F 31 184 4.55 12 104 2.125 36 0 0 16.6 4.2 1.40 20 340 ETA
CAM46 68 F 40 250 5.33 134 73 2.750 40 5 6 11.4 3.6 1.40 0 0 ABA
CAM52 55 F 34 60 2.90 22 40 3.000 2 1 1 7.4 1.1 0.70 0 0.7 LEF, MTX
CON1 54 F 41 n/a 5.75 2 8 1.125 75 7 20 11.4 3.9 0.80 0 n/a SSZ, HCQ
CON2 52 F 32 n/a 4.83 1 24 2.000 22 5 3 4.8 2.0 0.30 39 n/a AZA
CON3 65 F 20 n/a 2.04 1 2 1.375 14 0 1 4.4 0.4 0.90 179 152 TOC, SSZ
CON4 76 F 22 n/a 2.27 2 2 1.625 11 1 3 10.3 1.8 0.70 33 294 TOC, MTX
CON5 79 F 21 n/a 2.97 1 14 2.250 24 0 1 11.8 2.7 0.60 137 215 ABA, MTX
CON6 67 F 33 n/a 5.12 1 38 1.750 39 5 7 16.3 2.8 2.50 16 n/a ETA
CON7 54 F 20 n/a 2.03 2 14 0.250 4 0 0 9.3 1.2 1.30 0 1.2 MTX, SSZ, HCQ
CON8 58 M 27 n/a 5.11 1 9 2.125 55 1 17 9.6 1.8 1.00 275 340 MTX